Impact and cost-effectiveness of a second tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine dose to prevent pertussis in the United States
- PMID: 26899377
- DOI: 10.1016/j.vaccine.2016.02.027
Impact and cost-effectiveness of a second tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine dose to prevent pertussis in the United States
Abstract
Introduction: The United States experienced a substantial increase in reported pertussis cases over the last decade. Since 2005, persons 11 years and older have been routinely recommended to receive a single dose of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine. The objective of this analysis was to evaluate the potential impact and cost-effectiveness of recommending a second dose of Tdap.
Methods: A static cohort model was used to calculate the epidemiologic and economic impact of adding a second dose of Tdap at age 16 or 21 years. Projected costs and outcomes were examined from a societal perspective over a 20-year period. Quality-adjusted Life Years (QALY) saved were calculated.
Results: Using baseline pertussis incidence from the National Notifiable Diseases Surveillance System, Tdap revaccination at either age 16 or 21 years would reduce outpatient visits by 433 (5%) and 285 (4%), and hospitalization cases by 7 (7%) and 5 (5%), respectively. The costs per QALY saved with a second dose of Tdap were approximately US $19.7 million (16 years) and $26.2 million (21 years). In sensitivity analyses, incidence most influenced the model; as incidence increased, the costs per QALY decreased. To a lesser degree, initial vaccine effectiveness and waning of effectiveness also affected cost outcomes. Multivariate sensitivity analyses showed that under a set of optimistic assumptions, the cost per QALY saved would be approximately $163,361 (16 years) and $204,556 (21 years).
Conclusion: A second dose of Tdap resulted in a slight decrease in the number of cases and other outcomes, and that trend is more apparent when revaccinating at age 16 years than at age 21 years. Both revaccination strategies had high dollar per QALY saved even under optimistic assumptions in a multivariate sensitivity analysis.
Keywords: Adolescent; Adult; Cost-effectiveness; Pertussis; Revaccination; Tdap.
Published by Elsevier Ltd.
Similar articles
-
Economic impact of implementing decennial tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccination in adults in the United States.Vaccine. 2020 Jan 10;38(2):380-387. doi: 10.1016/j.vaccine.2019.09.104. Epub 2019 Oct 31. Vaccine. 2020. PMID: 31676198
-
Tetanus, diphtheria and acellular pertussis (Tdap) vaccine for prevention of pertussis among adults aged 19 years and older in the United States: A cost-effectiveness analysis.Prev Med. 2020 May;134:106066. doi: 10.1016/j.ypmed.2020.106066. Epub 2020 Mar 19. Prev Med. 2020. PMID: 32199910 Free PMC article.
-
Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.Pediatrics. 2006 Mar;117(3):965-78. doi: 10.1542/peds.2005-3038. Epub 2005 Dec 28. Pediatrics. 2006. PMID: 16382131
-
Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants recommendations of the Advisory Committee on Immunization Practices (ACIP).MMWR Recomm Rep. 2008 May 30;57(RR-4):1-51. MMWR Recomm Rep. 2008. PMID: 18509304 Review.
-
Acellular pertussis vaccine use in risk groups (adolescents, pregnant women, newborns and health care workers): a review of evidences and recommendations.Vaccine. 2012 Jul 27;30(35):5179-90. doi: 10.1016/j.vaccine.2012.06.005. Epub 2012 Jun 15. Vaccine. 2012. PMID: 22709953 Review.
Cited by
-
Review of the economic evidence presented to the United States Advisory Committee on Immunization Practices, 2012-2016.Vaccine. 2019 Jan 3;37(1):7-10. doi: 10.1016/j.vaccine.2018.11.055. Epub 2018 Nov 23. Vaccine. 2019. PMID: 30473183 Free PMC article.
-
Penicillin skin testing in methicillin-sensitive staphylococcus aureus bacteremia: A cost-effectiveness analysis.PLoS One. 2019 Jan 7;14(1):e0210271. doi: 10.1371/journal.pone.0210271. eCollection 2019. PLoS One. 2019. PMID: 30615655 Free PMC article.
-
Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccines: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2019.MMWR Morb Mortal Wkly Rep. 2020 Jan 24;69(3):77-83. doi: 10.15585/mmwr.mm6903a5. MMWR Morb Mortal Wkly Rep. 2020. PMID: 31971933 Free PMC article.
-
Lessons from a mature acellular pertussis vaccination program and strategies to overcome suboptimal vaccine effectiveness.Expert Rev Vaccines. 2022 Jul;21(7):899-907. doi: 10.1080/14760584.2021.1984891. Epub 2021 Oct 8. Expert Rev Vaccines. 2022. PMID: 34555994 Free PMC article.
-
Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP).MMWR Recomm Rep. 2018 Apr 27;67(2):1-44. doi: 10.15585/mmwr.rr6702a1. MMWR Recomm Rep. 2018. PMID: 29702631 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical